Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Thierry Marie Jahan, M.D.

Thierry Marie Jahan, M.D.

Professor of Medicine
Chair, Data and Safety Monitoring Committee
Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology
UCSF Helen Diller Family Comprehensive Cancer Center

Contact Information

(415) 885-3882  Appointments
(415) 353-7151  Clinic Fax
tjahan@medicine.ucsf.edu
Open Popup
  • 1977-1980, Université de Paris V-René Descartes, Paris France
  • 1980-1983, Columbia College, NYC, NY, BA, Psychology
  • 1983-1987, George Washington University School of Medicine, Washington, DC, M.D.
  • 1987-1988, Cedars Sinai Med. Ctr/UCLA, Los Angeles, CA, Internship, Internal Medicine
  • 1988-1990, Cedars Sinai Med. Ctr/UCLA, Los Angeles, CA, Resident, Internal Medicine
  • 1990-1991, Cedars Sinai Medical Ctr/UCLA, Los Angeles, CA, Kennamer Fellow in Internal Medicine
  • 1991-1994, UCSF, San Francisco, CA, Hematology/Oncology Fellow
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Medical Oncology
  • Department of Medicine, Division of Hematology Oncology, Thoracic Oncology Program
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • Novel agents in mesothelioma non-small cell lung cancer
  • French, Russian, Spanish

Thierry M. Jahan, M.D. is a renowned medical oncologist who specializes in the treatment of thoracic malignancies such as lung cancer and mesothelioma, and soft tissue sarcomas. Dr. Jahan received his M.D. from George Washington University, thereafter completing his residency and internal medicine residency at Cedars Sinai Medical Center in Los Angeles. He later was a clinical fellows in hematology and oncology at UCSF, eventually joining the UCSF faculty. Dr. Jahan co-founded the Thoracic Oncology Program with David Jablons, M.D. 

In addition to his keen clinical insight, Dr. Jahan is known by patients, their families and fellow clinicians for his sense of empathy and compassion. His steadfast commitment to eliminating the scourge of lung cancer is evidenced by the pins and ribbons adorning his white coat, a clear message of hope to patients.

In 2016, Dr. Jahan was inducted into the Council of Master Clinicians by the UCSF Department of Medicine, a select group of outstanding physicians with exceptional knowledge, superior teaching and communication skills, and the ability to provide compassionate, appropriate, effective, and high-quality patient care. 

Dr. Jahan has been the recipient of numerous awards including the Medical House Staff Outstanding Teacher Award and Friend of the Palliative Care Service Award. He is also a member of numerous professional organizations, including the American College of Physicians, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC) and the Association of Northern California Oncologists.

Dr. Jahan has authored or co-authored numerous peer-reviewed articles, book chapters and research abstracts and lectured nationally and internationally on lung cancer and mesothelioma. Numerous major media outlets including The San Francisco Chronicle, Time Magazine and KPIX San Francisco have sought out his opinions and observations on treatments and advances in lung cancer.

Dr. Jahan is Principal Investigator on numerous thoracic oncology clinical trials. He has a particular interest in testing target therapies in non-small cell lung cancer malignant mesothelioma as either single agents or in combination with chemotherapy and/or radiation.

 
Most recent publications from a total of 56
  1. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 Jul; 14(7):825-36. View in PubMed
  2. Jahan T, Hassan R, Alley E, Kindler H, Antonia S, Whiting C, Coussens L, Murphy AL, Thomas A, Brockstedt DG. 208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S156. View in PubMed
  3. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar; 14(3):255-64. View in PubMed
  4. Tinkle CL, Weinberg V, Braunstein SE, Wustrack R, Horvai A, Jahan T, O'Donnell RJ, Gottschalk AR. Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma. Sarcoma. 2015; 2015:913565. View in PubMed
  5. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24. View in PubMed
  6. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61. View in PubMed
  7. Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2014 Oct; 9(10):1532-9. View in PubMed
  8. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1; 20(23):5927-36. View in PubMed
  9. Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov; 15(6):426-32. View in PubMed
  10. Okoye CC, Jablons DM, Jahan TM, Kukreja J, Cardozo S, Yom SS. Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity. Am J Clin Oncol. 2014 Aug; 37(4):350-5. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Thierry Marie Jahan, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X